DMAC
NASDAQDiaMedica Therapeutics Inc.
Price$5.35-0.02 (-0.37%)
02:45 PM07:45 PM
News · 26 weeks31+140%
2025-12-142026-06-07
Mix2290d
- Insider9(41%)
- SEC Filings6(27%)
- Earnings4(18%)
- Other3(14%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Giuffre Randall Michael4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Kuntz Richard4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director O'Connor Daniel J.4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Lewis Tanya4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Semba Charles Pauling4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Director Parsons James T.4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Pauls Dietrich John4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by CFO & Secretary Kellen Scott4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Krop Julie4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
- PRDiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 3:45 PM ET Format: Corporate Presentation If you are interested in arranging a 1×1 meeting with management, please contact your conference representative. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving t
- SECDiaMedica Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- PRDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim Analysis Interim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging Between 300 and 728 Patients) is Recommended Interim Analysis Anticipated to be Completed Before Year-End 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the
- PRDiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its President and CEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th in New York City. Fireside Chat Details Date & Time: Tuesday, May 19, 2026 | 4:05-4:30 PM ET Location: InterContinental New York Barclay NY | 111 E 48th Street, New York, NY 10017 Mr. Pauls will also be available for one-on-one meetings with investors during the conference. About DiaMedica Therapeutics Inc. DiaM
- SECSEC Form 10-Q filed by DiaMedica Therapeutics Inc.10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- SECDiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- PRDiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsDM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment; Interim Analysis planned in 4Q 2026 $51.3 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027 Conference Call and Webcast on May 7 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the
- PRDiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 7, 2026 Time: 8:00 AM EDT / 7:00 AM CDT Web access: https://app.webinar.net/nG3yPzRP7wk Dial In: (646)
- SECSEC Form DEFA14A filed by DiaMedica Therapeutics Inc.DEFA14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- SECSEC Form DEF 14A filed by DiaMedica Therapeutics Inc.DEF 14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- SECSEC Form 10-K filed by DiaMedica Therapeutics Inc.10-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
- PRDiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business HighlightsReceived Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026. ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026. $60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027. Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT. DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal
- PRDiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 31, 2026 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/bxPLk6nkE0q Dial In: (646) 357-8766 Confe
- PRDiaMedica Therapeutics to Participate in Upcoming March Investor ConferencesDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, March 2, 2026, at 11:50 a.m. Eastern Time (ET) Barclays 28th Annual Global Healthcare Conference Miami, Florida Fireside chat with Rick Pauls, CEO on Wednesday, March 10, 2026, at 10:00 a.m. ET Leerink Partners Global Health
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DiaMedica Therapeutics Inc.SCHEDULE 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
- PRDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica's common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation. The stock options were approved by the Compensation Committee of the Board of Directors and i
DMAC FAQ
7 questionsWhat does DiaMedica Therapeutics Inc. do?
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica...Where does DMAC stock trade?
DiaMedica Therapeutics Inc. (DMAC) is listed on NASDAQ.What sector and industry is DMAC in?
DiaMedica Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did DiaMedica Therapeutics Inc. go public?
DiaMedica Therapeutics Inc. (DMAC) completed its IPO in 2018.What are analysts saying about DMAC?
DiaMedica Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2025-11-14. Recent price targets range from $700.00 to $3200.00.What companies are similar to DMAC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DMAC side-by-side with any of them on Quantisnow.How can I track DMAC on Quantisnow?
Quantisnow aggregates DiaMedica Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DMAC to receive live email and push alerts on every new disclosure.